U.S. Markets closed

Alector, Inc. (ALEC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.18+0.24 (+4.04%)
At close: 04:00PM EDT
6.18 0.00 (0.00%)
After hours: 04:31PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.94
Bid5.76 x 900
Ask6.21 x 1200
Day's Range5.76 - 6.20
52 Week Range5.76 - 15.39
Avg. Volume578,136
Market Cap511.095M
Beta (5Y Monthly)0.83
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Alector to Participate in Upcoming Healthcare Conferences

    SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences: Cowen 43rd Annual Health Care Conference (Boston, Massachusetts) Tuesday, March 7, 2023, at 10:30 a.m. ET, panel Stifel 2023 CNS Days (Virtual) Tuesday, March 28, 2023, at 12:00 p.m. ET, fireside chat A webcast of each conference presentatio

  • GlobeNewswire

    Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

    On track to complete enrollment in the INVOKE-2 Phase 2 clinical trial of AL002 in patients with early Alzheimer’s disease in Q3 2023, with data readout expected by Q4 2024 Preparing to engage with regulatory authorities in mid-2023 and targeting data readout from the pivotal INFRONT-3 clinical trial for latozinemab in early 2025 pending regulatory feedback Additional data from the INFRONT-2 Phase 2 clinical trial of latozinemab in FTD-C9orf72 expected during the second half of 2023 Company and

  • GlobeNewswire

    Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today announced that on December 6, 2022, the compensation committee of Alector’s board of directors granted 8 (eight) new employees options to purchase an aggregate of 91,851 shares of the company’s common stock and restricted stock units (RSUs) for an aggregate of 40,961 shares of the company’s common stock.